Combination Products: These products combine a drug with a biologic agent, found commonly in vaccines and therapeutic proteins.

Device-Drug Combination Products: These are products where a device is used to deliver a drug, for example, inhalers for respiratory medications.

Understanding these categories helps in selecting the appropriate regulatory pathway for submission. Additionally, the FDA has established the Office of Combination Products (OCP), which plays a pivotal role in determining the review center for each combination product. Factors influencing the regulatory pathway include the primary mode of action (PMOA) and the intended use of the product.

Step 2: Establishing Design Controls

Once you understand the regulatory landscape, the next step involves establishing design controls in compliance with the FDA’s Quality System Regulations (QSR), detailed in 21 CFR Part 820. Design controls are a set of practices and procedures established during the product’s development phase to assure that the products meet user needs and intended uses.

To implement effective design controls, it is essential to integrate them throughout the product lifecycle:

• Define User Needs: Conduct thorough research to ascertain the needs and requirements of intended users. Proper documentation of user needs is crucial as it forms the basis of product design.
• Establish Design Inputs: Convert the defined user needs into specific design inputs. These should be measurable and address aspects such as performance, safety, and regulatory requirements.
• Design Outputs: Create design outputs that are based on the design inputs. This involves generating specifications, drawings, and other representations of the design. Ensure that outputs convey the intended performance of the combination product.
• Conduct Design Reviews: Regularly scheduled design reviews should take place throughout development to ensure compliance with design inputs and refine outputs as necessary.
• Verification and Validation (V&V): Execute proper V&V activities to ensure the design meets the requirements and performs effectively. Verification ensures that the products have been built according to design specifications, while validation confirms that the product meets user needs in actual usage conditions.

Documentation throughout these activities is essential, as regulatory agencies may request evidence of compliance with these practices during the audit process.

Step 3: Preparing Submission Dossier

The preparation of the submission dossier for a drug-led combination product requires meticulous attention. Depending on the classification of the product, submissions may take the form of a New Drug Application (NDA), Biologics License Application (BLA), or a Premarket Approval (PMA) application. The selected pathway will depend largely on whether your product falls under FDA’s Center for Drug Evaluation and Research (CDER) or the Center for Devices and Radiological Health (CDRH).

The following components must be included in the submission dossier:

• Product Description: Offer a detailed overview of the combination product, including its physical, chemical, and biological characteristics.
• Intended Use: Clearly state the product’s intended use and indications for use, including who the end-users are (healthcare professionals, patients, etc.).
• Labeling: Provide drafts of proposed labeling, including indications, instructions for use, and summaries of clinical data. Accurate labeling is critical as it informs both practitioners and patients about the correct use of the product.
• Clinical Data: Include the results from clinical studies demonstrating safety and efficacy. For combination products, the clinical data should reflect the interactions between the drug and device components.
• Non-clinical Data: Any safety and toxicological data should be submitted, including biocompatibility and chemical analyses.
• Manufacturing Information: Share details about the manufacturing process, facilities, and quality control measures that ensure product consistency and compliance.

Preparing the submission dossier requires extensive collaboration across departments, including R&D, regulatory affairs, and quality assurance. Thorough documentation and proper format according to FDA guidance are vital to avoid delays in review and approval.

Step 4: Submission Strategies- The 510(k) and PMA Paths

Choosing the correct submission strategy is critical for the successful approval of drug-led combination products. Two predominant paths exist: the Premarket Approval (PMA) process and the 510(k) pathway. Each route has specific requirements that must be met based on the type of combination product being developed.

The 510(k) pathway is typically used for devices that are substantially equivalent to a legally marketed predicate device. The requirements for the 510(k) submission include:

• Identification of Predicate Device: You must identify a legally marketed device that is similar to your product in intended use and technological characteristics.
• Demonstration of Substantial Equivalence: Provide data that demonstrate how your product is as safe and effective as the predicate device.
• Performance Testing: Conduct and report on necessary performance testing to ensure product safety and efficacy.

The PMA pathway, on the other hand, is more rigorous and is required for high-risk devices that do not qualify for the 510(k) route. This process involves:

• Comprehensive Clinical Studies: Conducting extensive clinical trials to gather safety and efficacy data.
• Robust Manufacturing Details: Providing exhaustive documentation on the manufacturing processes to affirm compliance with FDA QSR.
• Sufficient Risk Management Information: Present a thorough risk assessment that identifies and mitigates potential risks associated with the combination product.

A strategy encompassing both pathways should be developed early in the product development phase to ensure appropriate resource allocation and adherence to regulatory requirements.

Step 5: Navigating the Review Process

After the submission of your combination product to the FDA, the review process begins. The length and complexity of the review depend on the classification of the product and the type of application submitted.

Key aspects of the review process include:

• FDA Classification: The FDA will classify the product to determine whether it is a drug, device, or biologic. The classification will significantly influence the review procedure.
• Review Team Assignment: An FDA review team consisting of experts from drug and device divisions will be assembled. For combination products, this may include professionals from both CDER and CDRH, as appropriate.
• Review Timeline: The FDA aims to complete 510(k) reviews within 90 days, while PMA applications can take up to 180 days or more, depending on the complexity and request for additional information or clarification.
• Communication with FDA: Maintaining open lines of communication during the review process is critical. The FDA often provides feedback during the review, which organizations should be prepared to address promptly.

Furthermore, utilize the FDA’s Guidance for Industry documents extensively, as they provide crucial information regarding what is expected during the review of combination products. These expectations guide the organization on how best to prepare themselves for regulatory questions that may arise.

Step 6: Post-Approval Commitments and Compliance

Upon approval of a combination product, organizations must adhere to post-marketing requirements set forth by the FDA. These may include continued reporting and compliance with FDA regulations regarding Quality System Regulations, labeling changes, and adverse events monitoring.

Key areas of focus post-approval include:

• Adverse Event Reporting: Organizations are responsible for monitoring and reporting adverse events associated with their products in accordance with FDA regulations. Establish systems to track and analyze data on unanticipated side effects or performance issues.
• Post-Market Surveillance Studies: In some cases, the FDA may require post-market studies to monitor the long-term safety and effectiveness of a combination product. These studies should be conducted under protocols that have been previously approved.
• Device Tracking Requirements: If the product involves a high-risk device, companies must comply with tracking requirements to trace products through the distribution chain.
• Changes to Manufacturing or Design: Any modifications to the product, such as changes in its design or manufacturing process that may impact safety or effectiveness, must be reported and may require a new submission.

Continuous compliance with regulatory expectations is essential for maintaining product availability in the market and safeguarding public health. Regular internal and external audits are recommended to ensure adherence to FDA guidelines as well as to maintain necessary documentation.

Conclusion

Successfully navigating the regulatory framework for drug-led combination products within the FDA’s guidelines requires an organized approach focused on understanding the complexities of each step in the product lifecycle. From establishing design controls to managing the post-approval phase, ensuring clear documentation and compliance with established practices is paramount for success. As regulations evolve, remaining proactive and informed will facilitate smoother navigation through the regulatory pathways for combination products.